It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Vascular smooth muscle cells (VSMCs) within atherosclerotic lesions undergo a phenotypic switching in a KLF4-dependent manner. Glycolysis plays important roles in transdifferentiation of somatic cells, however, it is unclear whether and how KLF4 mediates the link between glycolytic switch and VSMCs phenotypic transitions. Here, we show that KLF4 upregulation accompanies VSMCs phenotypic switching in atherosclerotic lesions. KLF4 enhances the metabolic switch to glycolysis through increasing PFKFB3 expression. Inhibiting glycolysis suppresses KLF4-induced VSMCs phenotypic switching, demonstrating that glycolytic shift is required for VSMCs phenotypic switching. Mechanistically, KLF4 upregulates expression of circCTDP1 and eEF1A2, both of which cooperatively promote PFKFB3 expression. TMAO induces glycolytic shift and VSMCs phenotypic switching by upregulating KLF4. Our study indicates that KLF4 mediates the link between glycolytic switch and VSMCs phenotypic transitions, suggesting that a previously unrecognized KLF4-eEF1A2/circCTDP1-PFKFB3 axis plays crucial roles in VSMCs phenotypic switching.
KLF4-induced phenotypic switching of vascular smooth muscle cells occurs in atherosclerosis. Now, KLF4 is shown to induce a glycolytic shift involving upregulation of PFKFB3 expression through circular RNA CTDP1 and eukaryotic elongation factor eEF1A2.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details

1 Hebei Medical University, Department of Biochemistry and Molecular Biology, the Key Laboratory of Neural and Vascular Biology, Ministry of Education of China, Shijiazhuang, China (GRID:grid.256883.2) (ISNI:0000 0004 1760 8442)
2 Hebei Medical University, Department of Biochemistry and Molecular Biology, the Key Laboratory of Neural and Vascular Biology, Ministry of Education of China, Shijiazhuang, China (GRID:grid.256883.2) (ISNI:0000 0004 1760 8442); The Second Hospital of Hebei Medical University, Department of Urology, Shijiazhuang, China (GRID:grid.452702.6) (ISNI:0000 0004 1804 3009)
3 Hebei Medical University, Department of Biochemistry and Molecular Biology, the Key Laboratory of Neural and Vascular Biology, Ministry of Education of China, Shijiazhuang, China (GRID:grid.256883.2) (ISNI:0000 0004 1760 8442); The Second Hospital of Hebei Medical University, Department of Emergency Medicine, Shijiazhuang, China (GRID:grid.452702.6) (ISNI:0000 0004 1804 3009)
4 Peking University, The Institute of Cardiovascular Sciences and Institute of Systems Biomedicine, School of Basic Medical Sciences, and Key Laboratory of Molecular Cardiovascular Sciences of Ministry of Education, Health Science Center, Beijing, China (GRID:grid.11135.37) (ISNI:0000 0001 2256 9319)
5 Capital Medical University, Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Beijing, China (GRID:grid.24696.3f) (ISNI:0000 0004 0369 153X)